Latest Breaking News On - Douglase onsi - Page 4 : comparemela.com

Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting

/PRNewswire/ Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today.

United statesUnited kingdomSouth koreaRepublic of koreaMatthew deyoungSamuelj klempnerDouglase onsiLeap therapeutics incPrnewswire leap therapeutics incDrug administrationAmerican society of clinical oncologyHarvard medical schoolClinical oncologyAnnual meetingPresentation detailsHarvard medical

Form 8-K LEAP THERAPEUTICS, INC For: Apr 12

Form 8-K LEAP THERAPEUTICS, INC For: Apr 12
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomDouglase onsiLeap therapeutics incSecurities exchangeSecurities exchange actZip codeSecurities actExchange actTherapeutics announces completionDefiance studyColorectal cancer patientsCurrent reportPage interactive dataExecutive officer

Leap Therapeutics : Announces Completion of Enrollment in Part A of the DeFianCe Study of - Form 8-K

Leap Therapeutics Announces Completion of Enrollment in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients Cambridge, MA -. | April 12, 2023

United kingdomMatthew deyoungCynthia sirardDouglase onsiLeap therapeutics incDrug administrationLeap therapeutics announces completionDefiance studyColorectal cancerChief medical officerLeap therapeuticsSeriesx non voting convertible preferred stockNasdaq globalAnnual reportNc stock exchangePress release

Leap Therapeutics Announces Completion of Enrollment in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

/PRNewswire/ Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced.

United kingdomMatthew deyoungCynthia sirardDouglase onsiPrnewswire leap therapeutics incLeap therapeutics incDrug administrationChief medical officerLeap therapeuticsSeriesx non voting convertible preferred stockNasdaq globalAnnual report

Form 8-K LEAP THERAPEUTICS, INC For: Apr 03

Form 8-K LEAP THERAPEUTICS, INC For: Apr 03
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesDouglase onsiCynthia sirardLeap therapeutics incSecurities exchangeSecurities exchange actZip codeSecurities actExchange actCertain officersCompensatory arrangementsChief medical officerSecond amendmentExecutive employment agreementGood reason